Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Expected Total Market Size Of The Claudin 18.2 Targeted Therapy Industry By The Forecast Year 2029?
The claudin 18.2 targeted therapy market has seen substantial expansion in its size over recent years. It is anticipated to grow from $1.29 billion in 2024 to $1.60 billion in 2025, reflecting a compound annual growth rate (CAGR) of 23.9%. The market’s historical growth can be linked to increasing research and development activities, enhanced government and institutional support, a rising incidence of pancreatic cancer, increased healthcare investments in oncology, and the expanding global availability of targeted therapies.
The claudin 18.2 targeted therapy market size is anticipated to experience substantial growth over the next few years. It is forecast to expand to $3.73 billion by 2029, achieving a compound annual growth rate (CAGR) of 23.6%. This expansion during the forecast period can be attributed to several factors, including the increasing approval of cldn18.2-targeted therapies, the rising prevalence of gastric and gastroesophageal junction (gej) cancers, an expanding pipeline of cldn18.2-directed therapies, growing interest from pharmaceutical companies, and the increasing adoption of personalized medicine. Prominent trends for the forecast period include technological advancements in monoclonal antibody development, innovations in bispecific antibody therapies, developments in antibody-drug conjugates, investment in biomarker discovery and validation, and continued research and development in combination therapies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28169&type=smp
Which Major Market Drivers Are Shaping The Future Of The Claudin 18.2 Targeted Therapy Market?
The increasing occurrence of gastrointestinal cancers is anticipated to boost the expansion of the claudin 18.2 targeted therapy market in the future. Gastrointestinal (GI) cancers are defined as malignant growths emerging in any segment of the digestive system, from the esophagus down to the rectum. This surge in gastrointestinal cancers is primarily attributable to poor dietary habits, characterized by high consumption of processed foods and insufficient fiber, which fosters gut inflammation and elevates the likelihood of cancer. Claudin 18.2 targeted therapy addresses gastrointestinal cancers by specifically focusing on the Claudin 18.2 protein, which is found in elevated levels on cancer cells. This mechanism allows drugs or antibodies to eradicate malignant cells while preserving healthy tissues, thereby enhancing the efficacy of treatment. As an illustration, in July 2025, data from the National Library of Medicine, a US-based federal government entity, revealed that in 2022, the five main gastrointestinal (GI) cancers led to 4,783,391 new diagnoses and 3,235,719 fatalities, making up 23.9% of all new cancer cases and 33.2% of all cancer-related deaths worldwide. Consequently, the growing frequency of gastrointestinal cancers is fueling the expansion of the Claudin 18.2 targeted therapy market.
What Are The Segment Types Shaping The Claudin 18.2 Targeted Therapy Market?
The claudin 18.2 targeted therapy market covered in this report is segmented as
1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types
2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications
3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations
4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies
3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors
How Are Emerging Market Trends Shaping The Claudin 18.2 Targeted Therapy Industry Landscape?
Leading companies operating within the claudin 18.2 targeted therapy market are concentrating on developing advanced solutions, such as monoclonal antibodies, to specifically target claudin 18.2-expressing cancer cells and improve treatment outcomes. A monoclonal antibody is a protein engineered in a laboratory to precisely bind to a single target, for instance, a protein on the surface of cancer cells, thereby assisting the immune system in identifying and attacking these cells. For example, in March 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval from Japan’s Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab) for the treatment of patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively attaches to the CLDN18.2 protein on tumor cells, activating the immune system to destroy them. Clinical trials indicated it significantly enhances progression-free and overall survival when administered with chemotherapy compared to chemotherapy alone. This innovative therapy presents a new, effective alternative for patients with HER2-negative, CLDN18.2-positive tumors, addressing an unmet need in aggressive gastric cancer.
Who Are The Top Performing Companies In The Claudin 18.2 Targeted Therapy Market In Recent Years?
Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/claudin-182-targeted-therapy-global-market-report
What Are The Key Regional Factors Influencing The Claudin 18.2 Targeted Therapy Market Growth?
Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2024. The regions covered in claudin 18.2 targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Claudin 18.2 Targeted Therapy Market Report:
https://www.thebusinessresearchcompany.com/customise?id=28169&type=smp
Browse Through More Reports Similar to the Global Claudin 18.2 Targeted Therapy Market 2025, By The Business Research Company
Targeted Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
Coronavirus Current Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report
Next Generation Antibody Therapeutics Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model